Shanghai Fosun Pharmaceutical Group Co Stock

Shanghai Fosun Pharmaceutical Group Co Debt 2024

Shanghai Fosun Pharmaceutical Group Co Debt

26,976.28 CNY

Ticker

600196.SS

ISIN

CNE000000X38

In 2024, Shanghai Fosun Pharmaceutical Group Co's total debt was 26,976.28 CNY, a 31.24% change from the 20,554.92 CNY total debt recorded in the previous year.

Shanghai Fosun Pharmaceutical Group Co Aktienanalyse

What does Shanghai Fosun Pharmaceutical Group Co do?

Shanghai Fosun Pharmaceutical Group Co Ltd is a Chinese company specializing in the healthcare industry. It was founded in 1994 and is headquartered in Shanghai. The company has grown to become one of the largest pharmaceutical conglomerates in China and operates internationally. The company's history began in the 1990s with the establishment of Shanghai Fosun High-Tech (Group) Co. Ltd. Through the acquisition of local pharmaceutical companies, Fosun quickly secured a place among the major players in the Chinese pharmaceutical market. From the beginning, the development, production, and marketing of pharmaceutical products and medical devices were the main focus. Today, Shanghai Fosun Pharmaceutical is a holding company with various subsidiaries operating in different areas of medicine. These include the development of innovative drugs, the production of generic drugs, and the business-to-consumer sector. The company generates an annual revenue of over six billion US dollars. One of Shanghai Fosun Pharmaceutical's most well-known products is the drug Alunbrig for the treatment of lung cancer. It is a tyrosine kinase inhibitor that inhibits the growth of cancer cells. Alunbrig has shown good results in clinical studies and is now approved for the treatment of lung cancer in many countries. Another important business area for Shanghai Fosun Pharmaceutical is the production of generic drugs. These are imitations of already approved, often expensive, original drugs. Fosun manufactures such medications at a significantly lower cost than the original manufacturer, making them more accessible to a broader population. In addition to drug development and generic production, Shanghai Fosun Pharmaceutical is also active in other areas of the healthcare industry. In recent years, the company has acquired several private hospitals in China and operates them under the name Fosun International Hospitals. Special emphasis is placed on state-of-the-art medical technology and patient-oriented care. Another important area is the manufacturing of medical devices. Shanghai Fosun Pharmaceutical works closely with partners from both domestic and foreign markets to develop innovative products. An example is the artificial hip joint, which was developed in collaboration with an American partner company. Fosun produces and distributes over 70 different types of medical devices. In summary, Shanghai Fosun Pharmaceutical Group is an innovative company specializing in various areas of the healthcare industry. Through its consistent focus on growth and innovation, Fosun has steadily expanded in recent years and has become one of the key players in the Chinese pharmaceutical market. However, the global expansion and ambitious goals also leave room for risks and mistakes. Shanghai Fosun Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Shanghai Fosun Pharmaceutical Group Co's Debt Structure

Shanghai Fosun Pharmaceutical Group Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Shanghai Fosun Pharmaceutical Group Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Shanghai Fosun Pharmaceutical Group Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Shanghai Fosun Pharmaceutical Group Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Shanghai Fosun Pharmaceutical Group Co stock

What is the debt of Shanghai Fosun Pharmaceutical Group Co this year?

Shanghai Fosun Pharmaceutical Group Co has a debt level of 26,976.28 CNY this year.

What was the debt of Shanghai Fosun Pharmaceutical Group Co compared to the previous year?

The debt of Shanghai Fosun Pharmaceutical Group Co has increased by 31.24% compared to the previous year increased.

What are the consequences of high debt for investors in Shanghai Fosun Pharmaceutical Group Co?

High debt can pose a risk for investors of Shanghai Fosun Pharmaceutical Group Co, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Shanghai Fosun Pharmaceutical Group Co?

Low debt means that Shanghai Fosun Pharmaceutical Group Co has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Shanghai Fosun Pharmaceutical Group Co affect the company?

An increase in debt of Shanghai Fosun Pharmaceutical Group Co can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Shanghai Fosun Pharmaceutical Group Co affect the company?

A reduction in debt of Shanghai Fosun Pharmaceutical Group Co can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Shanghai Fosun Pharmaceutical Group Co?

Some factors that can influence the debt of Shanghai Fosun Pharmaceutical Group Co include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Shanghai Fosun Pharmaceutical Group Co so important for investors?

The debts of Shanghai Fosun Pharmaceutical Group Co are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Shanghai Fosun Pharmaceutical Group Co take to change the debt?

To change the debt, Shanghai Fosun Pharmaceutical Group Co can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Shanghai Fosun Pharmaceutical Group Co pay?

Over the past 12 months, Shanghai Fosun Pharmaceutical Group Co paid a dividend of 0.42 CNY . This corresponds to a dividend yield of about 1.89 %. For the coming 12 months, Shanghai Fosun Pharmaceutical Group Co is expected to pay a dividend of 0.44 CNY.

What is the dividend yield of Shanghai Fosun Pharmaceutical Group Co?

The current dividend yield of Shanghai Fosun Pharmaceutical Group Co is 1.89 %.

When does Shanghai Fosun Pharmaceutical Group Co pay dividends?

Shanghai Fosun Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of August, July, September, September.

How secure is the dividend of Shanghai Fosun Pharmaceutical Group Co?

Shanghai Fosun Pharmaceutical Group Co paid dividends every year for the past 23 years.

What is the dividend of Shanghai Fosun Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.44 CNY are expected. This corresponds to a dividend yield of 2 %.

In which sector is Shanghai Fosun Pharmaceutical Group Co located?

Shanghai Fosun Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Fosun Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Fosun Pharmaceutical Group Co from 8/6/2024 amounting to 0.27 CNY, you needed to have the stock in your portfolio before the ex-date on 8/6/2024.

When did Shanghai Fosun Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 8/6/2024.

What was the dividend of Shanghai Fosun Pharmaceutical Group Co in the year 2023?

In the year 2023, Shanghai Fosun Pharmaceutical Group Co distributed 0.56 CNY as dividends.

In which currency does Shanghai Fosun Pharmaceutical Group Co pay out the dividend?

The dividends of Shanghai Fosun Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Fosun Pharmaceutical Group Co

Our stock analysis for Shanghai Fosun Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Fosun Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.